Dermatology

The future looks promising for alopecia areata patients as two JAK inhibitors have been tested in clinical trials while other treatment studies are ongoing. So what should clinicians know about these therapies? Learn more as Dr. Raj Chovatiya speaks to Dr. Britt Craiglow, Adjunct Associate Professor at the Yale School of Medicine and Double Board-Certified Dermatologist with Dermatology Physicians of Connecticut.

Initially approved for the treatment of rheumatoid arthritis, baricitinib is now the first FDA-approved treatment for patients with alopecia areata. So what can patients look forward to with this new therapy? Dive in with Dr. Raj Chovatiya as he’s joined by Dr. Britt Craiglow, Adjunct Associate Professor at the Yale School of Medicine and Double Board-Certified Dermatologist at Dermatology Physicians of Connecticut.

This episode of Rub Some Dirt in It is getting curiouser and curiouser. See if you can solve these two cases before host Marshall Miller reveals the rare and unexpected diagnoses.

Physician burnout remains a conversation, and the pandemic dramatically changed the landscape for dermatologists—for better and for worse. Omaha, NE-based Joel Schlessinger, MD, who serves as Chief Cosmetic Surgery Editor of Practical Dermatology® speaks with Las Vegas-based dermatologist H.L. Greenberg, MD, about the importance of physicians finding “multiple sources of happiness” in this episode of Practical Dermatology: The Podcast.

Proper access to medication can present challenges for the doctor and patient but is necessary to achieve optimal patient outcomes. So how can they work together to eliminate this burden? To discuss this further, Dr. Mary Katherine Cheeley is joined by Dr. Justin Cheeley, Assistant Professor in the Departments of General Internal Medicine and Dermatology and the Director of Inpatient Dermatology at Emory School of Medicine.

Patients with IBD, arthritis, or other disorders of the immune system may be at a higher risk for developing pyoderma gangrenosum (PG). So how can clinicians better manage their patients with PG? Explore this rare condition as Dr. Mary Katherine Cheeley is joined by Dr. Justin Cheeley, Assistant Professor in the Departments of General Internal Medicine and Dermatology and the Director of Inpatient Dermatology at the Emory School of Medicine.

Black, Hispanic, Asian, and other people of color with plaque psoriasis and psoriatic arthritis often face delayed diagnosis, misdiagnosis, and limited access to testing, treatment, and care. Determi-Nation, a new initiative sponsored by Janssen Pharmaceuticals, aims to change this. Patient advocate Alisha Bridges, Grace Wright, MD, PhD, president of the Association of Women in Rheumatology in New York City, and Naureen Kabani, MD, a rheumatologist with SUNY Downstate in Brooklyn, New York, discuss how this new program will help close gaps and improve access to care for people of color with psoriatic disease.

There’s no paucity of studies for biologic therapies used to treat psoriatic disease, but the number of head-to-head trials comparing these agents is limited. Enter network meta-analysis, a statistical methodology that has emerged over the past few years to compare medication. Philip Mease, MD, a clinical professor at the University of Washington School of Medicine and director of rheumatology research at the Swedish Medical Center in Seattle, and Dr. Wolf-Henning Boehncke, chair of the division of dermatology and venereology at Geneva University Hospitals, Switzerland, and full professor at the Department of Pathology and Immunology at Geneva University, discuss the use of network meta-analyses and potential pitfalls in choosing biologic therapies for patients with psoriasis and psoriatic arthritis in this episode of Practical Dermatology: The Podcast.

In 2014, the American Society for Laser Medicine and Surgery started its New Beginnings initiative. Initially launched to benefit cancer survivors, ASLMS physicians volunteered to remove radiation tattoos pro bono. Recently, the ASLMS, under the leadership of its president Paul Friedman, MD, expanded the philanthropic campaign to create the New Beginnings Branding Tattoo Removal Program and partnered with the National Trafficking Sheltered Alliance to connect board-certified physicians with sex trafficking survivors for pro bono laser removal of branding tattoos. Alisha Merlo, the Executive Director of Professional Relations at Colorescience, and dermatologists Dr. Friedman, Dr. Emily Guo, and Dr. Elizabeth Kream discuss the impact of this work and their goals for the future of this initiative. Listen now.

Getting the proper treatment for patients with psoriasis and psoriatic arthritis can be life-changing. So how can clinicians help patients find the right medication? To discuss this topic together, Dr. Matthew Keller is joined by fellow ReachMD host, Dr. Monica Schwartzman, who is also a Rheumatologist.